Nephro-Urology Monthly
Volume 17 · Issue 1 · e155319

OPEN PEER REVIEW

Montelukast as an Effective Drug for Cystitis in Asthmatic Pediatric Cases: A Clinical Trial Study

Mohamadreza Mokhtari, Fatemeh Dorreh, Parsa Yousefichaijan, Ali Arjmand Shabestari, Manijeh Kahbazi, Masoud Rezagholizamenjany

SUBMITTED	REVISED	ACCEPTED	DOI
20 Sep 2024	29 Dec 2024	1 Jan 2025	10.5812/numonthly-155319

About this report

This open peer review (OPR) report shows the public comments made on this article during peer review, by the reviewers, the associate editor and the editor-in-chief, for every revision round, together with the authors' replies. Comments appear only with the consent of the people who wrote them. Reviewers who chose to sign their report are named; the others are shown as "Referee". Comments are edited for language only, and confidential remarks to the editors are not included.

More about open peer review: brieflands.com/knowledgebase/opr

Contents

1 **Original submission** Associate Editor 2
2 **Revision 1** Associate Editor 3
Authors' reply to reviewers 4
Reviewer and editor comments 7

1 Original submission

1 comment · 2 Oct 2024

Associate Editor

MAJOR REVISION 2 Oct 2024

Major Revision

2

Revision 1

AUTHORS' RESPONSE TO REVIEWERS

Authors' reply to reviewers

The next pages contain the authors' point-by-point reply to the comments of this revision round, as submitted with the revised manuscript. It is published as the authors wrote it.

With Greetings

REVIEWER No. 1:

Comment 1:

The background section is short and concise and should clearly state the purpose of the study.

Answer:

A more complete introduction was added with the statement of aims and highlighted.

Comment 2:

Methodology section lacks details about study design. Specify whether this is a randomized controlled trial, observational study, or other design. This is very important to understand the validity of the findings.

Answer:

Study type added in methodology section and highlighted.

Comment 3:

Provide a reasonable sample size of 56 cases. Discuss whether this number is sufficient to achieve statistical power and how it was determined.

Answer:

This section was added and highlighted in study sample size.

Comment 4:

Present the results in a more structured format, possibly using tables or figures to summarize findings related to symptom improvement and statistical significance.

Answer:

Complete summarized data as tables given at the end of the article and highlighted.

Comment 5:

The discussion should provide a deeper analysis of the results in the context of the existing literature on the anti-inflammatory effects of Montelukast, especially on its mechanism of action in cystitis. Also, this section of discussion should explore the potential mechanisms by which Montelukast may affect cystitis symptoms.

Answer:

Discussion about potential mechanisms of Montelukast on cystitis was add and highlighted.

Comment 6:

Ensure consistent terminology throughout the article (eg, use "intervention group" or "treatment group" consistently).

Answer:

This

Comment 7:

Clarify how to define and measure symptoms, especially terms such as "suprapubic pain" and "scrotal pain."

Answer:

This point has been corrected.

Comment 8:

Make sure all references are formatted according to a specific citation style (eg APA, AMA).

Answer:

All references are based on citation style.

Comment 9:

Conclusions could be strengthened by more clearly summarizing key findings and discussing their implications for clinical practice.

Answer:

In conclusion the significant finding and its clinical application is stated.

Comment 10:

Include a section on potential limitations of the study, such as sample size, duration of treatment, or lack of long-term follow-up data.

Answer:

This section was added at end of article.

Comment 11:

Conclude with suggestions for future research, especially studies that could investigate different doses or longer durations of treatment.

Answer:

This section was added and highlighted.

Thanks

2 Revision 1

1 comment · 1 Jan 2025

Associate Editor

ACCEPT 1 Jan 2025

Accept